← Human Trials & Peer-Reviewed Studies
Low growth hormone secretion associated with post-acute sequelae SARS-CoV-2 infection (PASC) neurologic symptoms: A case-control pilot study.
Plain-language guide to PMID 37816478 (2024): pilot observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 37816478
- Journal
- Molecular and cellular endocrinology
- Year
- 2024
- Study type
- Observational Study
- Authors
- Wright TJ et al. (17 authors)
- DOI
- 10.1016/j.mce.2023.112071
- Registered trial
- NCT04860869
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this observational study publication.
To determine if patients that develop lingering neurologic symptoms of fatigue and "brain fog" after initial recovery from coronavirus disease 2019 (COVID-19) have persistent low growth hormone (GH) secretion as seen in other conditions with similar symptom etiology.
PASC and non-PASC subjects were tested for neurocognition and GH secretion, and given questionnaires to assess symptom severity.
Who Took Part
In this case-control observational pilot study, patients reporting lingering neurologic post-acute sequelae of SARS-CoV-2 (PASC, n = 10) symptoms at least 6 months after initial infection were compared to patients that recovered from COVID-19 without lingering symptoms (non-PASC, n = 13).
PASC subjects were also tested for glucose tolerance and adrenal function.
How the Study Was Run
In design terms this was a pilot study.
It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.
The researchers compared basic blood chemistry and select metabolites, lipids, hormones, inflammatory markers, and vitamins between groups.
What Was Measured
Topics PubMed links to this paper include COVID-19, SARS-CoV-2, Pilot Projects, Quality of Life, Case-Control Studies, Disease Progression and Fatigue.
The authors tagged it with the keywords Biomarkers, Cognition, Depression, Gastrointestinal, Growth hormone and Long COVID.
What This Means in Plain Language
The paper is a pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2024 (Molecular and cellular endocrinology), a journal based in Ireland.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.